Melanoma Vaccine Charlotte NC

A vaccine for advanced melanoma has shown promise in a new study. Melanoma is the most serious type of skin cancer in Charlotte. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

Vincent Voci
(704) 333-8300
2620 East 7th Street
Charlotte, NC
Specialties
Cosmetic Surgery
Insurance
Medicare Accepted: No
Workmens Comp Accepted: No
Accepts Uninsured Patients: No
Emergency Care: No


Data Provided by:
Galen Grayson, MD
(704) 295-0001
817 E Morehead St
Charlotte, NC
Business
Genesis Eye Center
Specialties
Ophthalmology

Data Provided by:
Michael Norman
(704) 446-1422
1000 Blythe Blvd
Charlotte, NC
Specialties
Pediatrics

Data Provided by:
Hope Peek, L.Ac., MSOM, Dipl. OM (NCCAOM)
(704) 595-9878
700 East Boulevard
Charlotte, NC
Business
Charlotte Acupuncture and Wellness Center, In
Specialties
Acupuncture, Chinese Herbal Medicine Tui Na Acupressure Nutritional Therapy Thermal Therapies
Doctor Information
Residency Training: Master of Science in Oriental Medicine
Medical School: Southwest Acupuncture College - Santa Fe, NM,
Additional Information
Member Organizations: AAOM NCAAOM


Data Provided by:
Pai Clinic of Chiropractic & Sports Medicine
(704) 599-0900
8821 University East Dr #100
Charlotte, NC

Data Provided by:
ChiroMed Plus
(704) 341-5200
6401 Carmel Rd.
Charlotte, NC

Data Provided by:
Todd Trembula, L.Ac., MSOM, Dipl. OM (NCCAOM)
(704) 595-9878
700 East Boulevard
Charlotte, NC
Business
Charlotte Acupuncture and Wellness Center, In
Specialties
Acupuncture, Chinese Herbal Medicine Tui Na Acupressure Nutritional Therapy Thermal Therapies
Doctor Information
Residency Training: Master of Science in Oriental Medicine
Medical School: Southwest Acupuncture College - Santa Fe, NM,
Additional Information
Member Organizations: AAOM NCAAOM


Data Provided by:
Thomas A Roberts Jr., MD
(704) 377-4009
2015 Randolph Rd
Charlotte, NC
Business
Charlotte Gastroenterology & Hepatology PLLC
Specialties
Gastroenterology

Data Provided by:
Carolinas Veterinary Medical Hospital
(704) 752-7227
10330 Feld Farm Lane
Charlotte, NC

Data Provided by:
Dr. Alexis P. Sage , Mobile Equine and Housec
(704) 231-8993
3627 Chilham Place
Charlotte, NC

Data Provided by:
Data Provided by:

Melanoma Vaccine

Provided By:

SATURDAY, May 30 (HealthDay News) --A vaccine for advanced melanoma has shown promise in a new study.

Melanoma is the most serious type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

The study, a phase 3 clinical trial involving 185 people, found that using the peptide vaccine in combination with the immunotherapy drug Interleukin-2 improved response rates and progression-free survival, according to University of Texas M.D. Anderson Cancer Center researchers, who said it was the first phase 3 trial to show a clinical benefit in a vaccine for melanoma.

Response rate and progression-free survival were 22.1 percent and 2.9 months, respectively, in people given the vaccine, compared with 9.7 percent and 1.6 months for those who were not vaccinated. Median overall survival was 17.6 months for the vaccine group and 12.8 months for the others.

The study, which was to be presented Saturday at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla., was funded in part by Novartis, which makes Interleukin-2.

"Obviously this is a disease, in its advanced setting, in need of better therapies for our patients," study co-author Dr. Patrick Hwu, a professor and chairman of M.D. Anderson's Department of Melanoma Medical Oncology, said in a news release from the center.

"While more follow-up is needed, this study serves as a proof-of-principle for vaccines' role in melanoma and in cancer therapy overall," Hwu said. "If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue."

The vaccine, called gp100:209-217 (200M), works by stimulating T-cells, which control immune response.

"This vaccine activates the body's cytotoxic T-cells to recognize antigens on the surface of the tumor," Hwu said. "The T-cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it to disintegrate."

More information

The Skin Cancer Foundation has more about melanoma.

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com